Close

Delcath Systems (DCTH) Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom

Go back to Delcath Systems (DCTH) Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom

Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom

April 21, 2021 8:38 AM EDT

NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the United Kingdoms (UK) National Institute for Health and Care Excellence (NICE), through the Interventional Procedures Advisory Committee, has updated its guidance for the Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) in the treatment of patients with metastases in the liver from Ocular Melanoma.

Previously, the NICE guidance recommended CHEMOSAT only be used in the context of formal research studies.... More